Handelsbanken Fonder AB Has $2.14 Million Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Handelsbanken Fonder AB grew its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 8.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,316 shares of the company’s stock after buying an additional 1,700 shares during the period. Handelsbanken Fonder AB’s holdings in HealthEquity were worth $2,141,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wasatch Advisors LP raised its stake in HealthEquity by 6.6% in the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock valued at $635,065,000 after purchasing an additional 483,269 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its position in HealthEquity by 36.7% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after acquiring an additional 226,563 shares during the last quarter. Barclays PLC increased its position in HealthEquity by 209.3% during the 3rd quarter. Barclays PLC now owns 166,492 shares of the company’s stock worth $13,628,000 after purchasing an additional 112,667 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of HealthEquity by 33.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 293,624 shares of the company’s stock valued at $24,033,000 after acquiring an additional 73,404 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new position in HealthEquity in the third quarter valued at about $5,675,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Trading Down 1.8 %

Shares of NASDAQ:HQY opened at $107.45 on Wednesday. HealthEquity, Inc. has a 1 year low of $65.01 and a 1 year high of $115.59. The stock’s fifty day moving average price is $104.31 and its 200-day moving average price is $92.89. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The company has a market cap of $9.31 billion, a P/E ratio of 98.58, a PEG ratio of 1.60 and a beta of 0.55.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Monday, December 9th. The company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.12). HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same period in the prior year, the business posted $0.40 EPS. Sell-side analysts expect that HealthEquity, Inc. will post 2.32 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on HQY. BTIG Research boosted their price objective on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Raymond James lifted their price objective on shares of HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday. Bank of America boosted their target price on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Barrington Research upped their price objective on shares of HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, December 2nd. Finally, Mizuho started coverage on HealthEquity in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price objective for the company. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $112.38.

Insider Buying and Selling

In related news, Director Stuart B. Parker sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the transaction, the director now owns 19,061 shares of the company’s stock, valued at $1,843,579.92. This trade represents a 56.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $111.29, for a total transaction of $639,917.50. Following the sale, the director now directly owns 78,219 shares of the company’s stock, valued at $8,704,992.51. This represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,000 shares of company stock worth $3,895,788. Corporate insiders own 2.20% of the company’s stock.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.